A Biofourmis team member will be in contact soon to schedule your demo. In the meantime, stay up-to-date with the latest Biofourmis news by following us on LinkedIn and Twitter.
What Our Customers Are Saying
“Through the partnership with Biofourmis, a leading company in research, development and commercialization of digital therapeutics, Chugai will set out to objectively assess pain associated with endometriosis and better understand its pathology.”
"The Everion® biosensor has become part of my daily habit. I wear it and forget about it and I know a care team is always there to make sure I am safe."
"The goal of this program is to leverage Biovitals® to remotely monitor patients and identify COVID-19 related physiological biomarkers that indicate deterioration in patients."
Since its founding in 2015, digital therapeutics and remote monitoring startup Biofourmis has been trying to figure out how to move healthcare beyond the pill.
Forbes partnered with venture firms Sequoia Capital and Meritech Capital to create our second annual AI 50, a list of private, U.S.-based companies that are using artificial intelligence in meaningful business-oriented ways.
In 2019, digital health companies from 18 countries spanning 17 overarching categories were selected for the first-ever annual CB Insights Digital Health 150.
Biofourmis had to present their innovation and demonstrate how virtual care and digital therapeutics can disrupt clinical trials to an esteemed panel of judges, followed by a rigorous Q&A.
